Literature DB >> 11313744

Premature termination mutations in exon 3 of the SMN1 gene are associated with exon skipping and a relatively mild SMA phenotype.

V Sossi1, A Giuli, T Vitali, F Tiziano, M Mirabella, A Antonelli, G Neri, C Brahe.   

Abstract

Autosomal recessive spinal muscular atrophy (SMA) is a common motor neuron disease caused by absence or mutation in the survival motor neuron (SMN1) gene. SNM1 and a nearly identical copy, SMN2, encode identical proteins, but SMN2 only produces a little full length protein due to alternative splicing. The level of functional SMN protein and the number of SMN2 genes correlate with the clinical phenotype ranging from severe to very mild. Here, we report on premature termination mutations in SMN1 exon 3 (425del5 and W102X) which induce skipping of the mutated exon. The novel nonsense mutation W102X was detected in two patients with a relatively mild phenotype who had only two copies of the SMN2 gene, a number that has previously been found associated with the severe form of SMA. We show that the shortened transcripts are translated into predicted in frame protein isoforms. Aminoglycoside treatment suppressed the nonsense mutation in cultured cells and abolished exon skipping. Fibroblasts from both patients show a high number of nuclear structures containing SMN protein (gems). These findings suggest that the protein isoform lacking the exon 3 encoded region contributes to the formation of the nuclear protein complex which may account for the milder clinical phenotype.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313744     DOI: 10.1038/sj.ejhg.5200599

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  16 in total

1.  Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: clues from a biomarker study.

Authors:  Francesco D Tiziano; Rosa Lomastro; Lorena Di Pietro; Maria Barbara Pasanisi; Stefania Fiori; Carla Angelozzi; Emanuela Abiusi; Corrado Angelini; Gianni Sorarù; Alessandra Gaiani; Tiziana Mongini; Liliana Vercelli; Gessica Vasco; Giuseppe Vita; Gian Luca Vita; Sonia Messina; Luisa Politano; Luigia Passamano; Grazia Di Gregorio; Cristina Montomoli; Chiara Orsi; Angela Campanella; Renato Mantegazza; Lucia Morandi
Journal:  Eur J Hum Genet       Date:  2012-10-17       Impact factor: 4.246

2.  Mutations in Subunits of the Activating Signal Cointegrator 1 Complex Are Associated with Prenatal Spinal Muscular Atrophy and Congenital Bone Fractures.

Authors:  Ellen Knierim; Hiromi Hirata; Nicole I Wolf; Susanne Morales-Gonzalez; Gudrun Schottmann; Yu Tanaka; Sabine Rudnik-Schöneborn; Mickael Orgeur; Klaus Zerres; Stefanie Vogt; Anne van Riesen; Esther Gill; Franziska Seifert; Angelika Zwirner; Janbernd Kirschner; Hans Hilmar Goebel; Christoph Hübner; Sigmar Stricker; David Meierhofer; Werner Stenzel; Markus Schuelke
Journal:  Am J Hum Genet       Date:  2016-02-25       Impact factor: 11.025

Review 3.  Advances in therapeutic development for spinal muscular atrophy.

Authors:  Matthew D Howell; Natalia N Singh; Ravindra N Singh
Journal:  Future Med Chem       Date:  2014-06       Impact factor: 3.808

Review 4.  Evolutionary conservation and expression of human RNA-binding proteins and their role in human genetic disease.

Authors:  Stefanie Gerstberger; Markus Hafner; Manuel Ascano; Thomas Tuschl
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

5.  Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene.

Authors:  Laura Alías; Sara Bernal; Pablo Fuentes-Prior; María Jesus Barceló; Eva Also; Rebeca Martínez-Hernández; Francisco J Rodríguez-Alvarez; Yolanda Martín; Elena Aller; Elena Grau; Ana Peciña; Guillermo Antiñolo; Enrique Galán; Alberto L Rosa; Miguel Fernández-Burriel; Salud Borrego; José M Millán; Concepción Hernández-Chico; Montserrat Baiget; Eduardo F Tizzano
Journal:  Hum Genet       Date:  2008-12-03       Impact factor: 4.132

Review 6.  Making sense of nonsense GABA(A) receptor mutations associated with genetic epilepsies.

Authors:  Jing-Qiong Kang; Robert L Macdonald
Journal:  Trends Mol Med       Date:  2009-08-31       Impact factor: 11.951

7.  A new series of small molecular weight compounds induce read through of all three types of nonsense mutations in the ATM gene.

Authors:  Liutao Du; Michael E Jung; Robert Damoiseaux; Gladys Completo; Francesca Fike; Jin-Mo Ku; Shareef Nahas; Cijing Piao; Hailiang Hu; Richard A Gatti
Journal:  Mol Ther       Date:  2013-06-18       Impact factor: 11.454

8.  Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model.

Authors:  Ming Du; Kim M Keeling; Liming Fan; Xiaoli Liu; Timea Kovaçs; Eric Sorscher; David M Bedwell
Journal:  J Mol Med (Berl)       Date:  2006-03-16       Impact factor: 4.599

9.  A novel mutation at the N-terminal of SMN Tudor domain inhibits its interaction with target proteins.

Authors:  Tomohiro Kotani; Retno Sutomo; Teguh Haryo Sasongko; Ahmad Hamim Sadewa; Toshinori Minato; Emiko Fujii; Shoichi Endo; Myeong Jin Lee; Hitoshi Ayaki; Yosuke Harada; Masafumi Matsuo; Hisahide Nishio
Journal:  J Neurol       Date:  2007-04-06       Impact factor: 4.849

10.  Nonaminoglycoside compounds induce readthrough of nonsense mutations.

Authors:  Liutao Du; Robert Damoiseaux; Shareef Nahas; Kun Gao; Hailiang Hu; Julianne M Pollard; Jimena Goldstine; Michael E Jung; Susanne M Henning; Carmen Bertoni; Richard A Gatti
Journal:  J Exp Med       Date:  2009-09-21       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.